Milestone for the field of personalized medicine
- 21 February 2023
It is well known that between 4 and 10% of patients with a specific genetic profile, who take specific drugs prescribed to them, will experience severe adverse side effects that frequently require medical attention and may even result in death.
The advantages of prescribing medications to patients based on their genetic information have been demonstrated, showing this for the first time in clinical practice across several EU countries thanks to U-PGx (EU-funded project).
When the dosage of the medication was matched to the patient's DNA traits, the research team from the Netherlands, led by Leiden University Medical Centre (LUMC), was able to demonstrate a significant reduction in drug side effects.
This significant achievement is a milestone for the field of personalized medicine, where the European Union has long funded initiatives. Tailoring medical care to the individual is crucial to deliver accurate diagnoses and efficient treatments.
We will be following the future developments!
AFFIRMO project as well wants to overcome the fragmentation of care for Atrial Fibrillation (AF) to an integrated care strategy designed to be patient-centred, by developing a holistic care approach based on the 'Atrial Fibrillation Better Care'(ABC) model.
